Neomatrix Formulations

NMT has discovered a new class of peptide drugs that limit burn injury progression. In addition, NMT in collaboration with other companies is developing the use of FDA approved devices that can noninvasively track burn injury progression and that can debirde burn eschar without damage to underlying viable tissue. 

Contact Information:

Dr. Richard Clark, President
Phone: 631-444-7519